WCLC 2025

September 06-09, 2025
Barcelona, Spain

The IASLC World Conference on Lung Cancer 2025

Explore more Oncology congress materials

Results(2)

Oncology

Safety of lurbinectedin + atezolizumab as 1L maintenance treatment in ES-SCLC: results from the Phase 3 IMforte study

Author(s): Martin Reck, Hossein Borghaei, Stephen V. Liu et al.

Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer: Updates From Jazz EMERGE 402

Author(s): Balazs Halmos, Philip Lammers, Geoffrey Liu et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.